Subcutaneous Immunoglobulin (SCIG) Global Market Report 2024

The subcutaneous immunoglobulin market size has grown rapidly in recent years. It will grow from $11.19 billion in 2023 to $12.72 billion in 2024 at a compound annual growth rate (CAGR) of 13.7%. The growth in the historic period can be attributed to the increased prevalence of immunodeficiency disorders, a rise in patient preference for home-based care, enhanced therapeutic efficacy, growth in awareness and diagnosis rates, and favorable reimbursement policies.

The subcutaneous immunoglobulin market size is expected to see rapid growth in the next few years. It will grow to $21.38 billion in 2028 at a compound annual growth rate (CAGR) of 13.9%. The growth in the forecast period can be attributed to the growing prevalence of neurological disorders, increasing prevalence of autoimmune diseases, rising awareness and acceptance of immunoglobulin therapy, expanding applications in neurology and dermatology, and the expansion of healthcare facilities. Major trends in the forecast period include advancements in drug delivery systems, increasing demand for home infusion therapies, developments in antibody therapy, innovations in formulations, and advancements in SCIG technology.

The rising prevalence of secondary immunodeficiency diseases is expected to drive the growth of the subcutaneous immunoglobulin market in the future. Secondary immunodeficiency diseases are characterized by a compromised immune system due to factors other than inherent immune system deficiencies. This prevalence is fueled by factors such as aging populations, the use of immunosuppressive therapies, and exposure to environmental toxins. Subcutaneous immunoglobulin therapy delivers antibodies to bolster the weakened immune system, particularly in chronic conditions such as HIV or autoimmune disorders, thereby preventing infections and supporting immune function during treatment. For example, in October 2023, the UK Health Security Agency reported 3,805 new HIV diagnoses in England in 2022, marking a 22% increase from the previous year. Hence, the rising prevalence of secondary immunodeficiency diseases is propelling the growth of the subcutaneous immunoglobulin market.

The growing incidence of neurological disorders is also expected to contribute to the expansion of the subcutaneous immunoglobulin market. Neurological disorders encompass a range of conditions affecting the nervous system, characterized by anatomical, biochemical, or electrical abnormalities in the brain, spinal cord, or peripheral nerves. Factors such as aging populations, environmental pollutants, genetic predispositions, and lifestyle changes contribute to the increasing prevalence of neurological disorders. Subcutaneous immunoglobulin therapy can be beneficial in these disorders by providing antibodies that modulate immune responses, reduce inflammation, and stabilize neuromuscular junctions, potentially slowing disease progression and improving symptoms. For instance, according to the Alzheimer's Association, 6.5 million Americans aged 65 and older are living with Alzheimer's dementia, with projections suggesting this number could double to 13.8 million by 2060. Hence, the rising number of neurological disorders is driving the growth of the subcutaneous immunoglobulin market.

Leading companies in the subcutaneous immunoglobulin market are developing subcutaneous human immunoglobulin (SCIG) formulations to enhance their product portfolios and offer more treatment options for patients with primary immunodeficiency diseases. SCIG refers to human immunoglobulin formulations for subcutaneous administration, designed specifically for treating primary immunodeficiency diseases. For example, in March 2022, Grifols S.A. introduced XEMBIFY 20% SCIG, a ready-to-use formulation for treating primary immunodeficiency, addressing a significant medical need for individuals with weakened immune systems. XEMBIFY offers simplified treatment procedures and increased patient convenience, as it remains stable at room temperature for up to 24 months, eliminating the need for refrigeration during storage and transport, which is advantageous in various healthcare settings.

Major companies operating in the subcutaneous immunoglobulin (SCIG) market are Pfizer Inc., Johnson & Johnson, Prothena Corporation plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Behring, Lonza Group, Grifols S.A., Octapharma AG, Dr. Reddy's Laboratories, Intas pharmaceutical Ltd., Emergent BioSolutions Inc., Kedrion Biopharma, LFB group, Biotest AG, Argenx SE, Bio Products Laboratory Ltd., ADMA Biologics Inc., Sino Biological Inc., Bharat Serums and Vaccines Limited (BSV), Kamada Pharmaceuticals, CinnaGen Co., Shire plc.

North America was the largest region in the subcutaneous immunoglobulin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the subcutaneous immunoglobulin (SCIG) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the subcutaneous immunoglobulin (SCIG) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Subcutaneous immunoglobulin (SCIG) refers to a method of administering immunoglobulin therapy where the medication is injected under the skin, rather than into a vein. This approach allows for slower absorption of the medication, which can reduce the risk of side effects compared to intravenous administration. SCIG is commonly used to treat various immune deficiencies, providing a convenient and effective way to boost the immune system.

The main types of SCIG products include immunoglobulin A (IgA), immunoglobulin G (IgG), and immunoglobulin M (IgM). IgA is an antibody type crucial for immune defense at mucosal surfaces, helping prevent pathogens from entering the body through mucosal membranes. These products find applications in primary immunodeficiency disorders, autoimmune diseases, neurological disorders, and other conditions, and they are used by various end-users such as clinics, hospitals, homecare settings, and others.

The subcutaneous immunoglobulin (SCIG) market research report is one of a series of new reports that provides subcutaneous immunoglobulin (SCIG) market statistics, including the subcutaneous immunoglobulin (SCIG) industry global market size, regional shares, competitors with subcutaneous immunoglobulin (SCIG) market share, detailed subcutaneous immunoglobulin (SCIG) market segments, market trends, and opportunities, and any further data you may need to thrive in the subcutaneous immunoglobulin (SCIG) industry. These subcutaneous immunoglobulin (SCIG) market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The subcutaneous immunoglobulin (SCIG) market consists of revenues earned by entities by providing services such as immune system support, home-based therapy, infection prevention, personalized dosing, patient training, and support. The market value includes the value of related goods sold by the service provider or included within the service offering. The subcutaneous immunoglobulin market also includes sales of infusion pumps, needles and catheters, syringes, and sharps disposal containers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.